Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/16/2017 02/17/2017 02/21/2017 02/22/2017 02/23/2017 Date
11.75(c) 11.8(c) 12.6(c) 12.15(c) 11.7 Last
607 206 402 863 2 406 317 5 288 294 397 209 Volume
-2.89% +0.43% +6.78% -3.57% -3.70% Change
More quotes
Financials ($)
Sales 2016 223 M
EBIT 2016 107 M
Net income 2016 17,7 M
Debt 2016 141 M
Yield 2016 -
Sales 2017 228 M
EBIT 2017 133 M
Net income 2017 66,8 M
Debt 2017 93,6 M
Yield 2017 -
P/E ratio 2016 24,80
P/E ratio 2017 6,79
EV / Sales2016 3,13x
EV / Sales2017 2,85x
Capitalization 557 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs in the Americas, Europe and Asia.It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic and... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
02/09 Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Lee..
01/09 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Regulation FD Disclosu..
01/09 SUCAMPO PHARMACEUTICALS : Announces Pricing of $260.0 Million 3.25% Convertible ..
01/09 SUCAMPO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements a..
2016 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Entry into a Material ..
2016 SUCAMPO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Crea..
2016 SUCAMPO PHARMACEUTICALS : Announces Pricing of $260.0 Million 3.25% Convertible ..
2016 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Announces Its New Debt Offering Of ..
2016 Sucampo Announces Pricing of $260.0 Million 3.25% Convertible Senior Notes du..
2016 SUCAMPO PHARMACEUTICALS : Announces Proposed Convertible Senior Note Offering
More news
Sector news : Bio Therapeutic Drugs
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on SUCAMPO PHARMACEUTICALS, I 
2015The bullish trend is not over
More Strategies
Latest Tweets
02:41p$INDXCH: Index Changes Reminder: Sucampo Pharmaceuticals (SCMP) will replace .. 
02/22TrndgDwn $SHLD $GV $EXAS $SCMP $GBT $HCLP Autocharts @  
02/21Sucampo Pharmaceuticals downgraded by Zacks Investment Research to hold.  
02/21Pitchers reporting to camp post these ideas in their shiny new lockers $LMOS .. 
02/17$SCMP $NILE Sucampo Pharmaceuticals Inc. will replace Blue Nile Inc. in the S.. 
More tweets
Qtime:16
News from SeekingAlpha
01/18 BIOTECH FORUM DAILY DIGEST : Sector Gets 'Trumped' Again - Spotlight On Sucampo ..
2016 Recent analyst action
2016 Midday Gainers / Losers
2016 After-hours Gainers / Losers
2016 Sucampo readies $225M private offering of convertible debt; shares slip 5% af..
Advertisement
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Technical analysis trends SUCAMPO PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 17,3 $
Spread / Average Target 43%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Daniel P. Getman Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICAL..-7.01%557
AMGEN, INC.18.42%127 119
CELGENE CORPORATION3.19%92 788
GILEAD SCIENCES, INC.-3.24%90 681
REGENERON PHARMACEUTIC..1.23%39 273
ACTELION LTD22.45%28 907
More Results